RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Trial Will Evaluate Niraparib vs Placebo in Platinum-Sensitive Patients with Ovarian Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 14
OP 14
DO 10.1177/155989771436010
UL http://mdc.sagepub.com/content/14/36/14.1.abstract
AB Niraparib is a potent oral PARP1 and PARP2 (poly [ADP-ribose] polymerase) inhibitor with antitumor activity in germline BRCA mutation (gBRCAmut) ovarian cancer and BRCA-negative (non-gBRCAmut) high-grade serous ovarian cancer (HGSOC). This article presents the study design of an ongoing niraparib maintenance study examining platinum-sensitive patients with ovarian cancer and deleterious gBRCAmut or high-grade serous histology non-gBRCAmut [NOVA; NCT01847274].